Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergy Therapeutics Progresses Grass And Peanut Allergy Vaccines, Plans For US Entry

Executive Summary

Clinical studies of grass allergy and peanut allergy vaccines are expected to start this year, as the UK specialty company plots its entry into the US.

 

You may also be interested in...



Aimmune Lays Foundations In Europe For Lead Peanut Allergy Therapeutic

With Aimmune’s AR101 oral immunotherapeutic nearing the market in the EU and US, the company sketches out its European business strategy after ARTEMIS meets its primary endpoint.

 

Can Denmark's ALK-Abello Crack The US Allergy Market?

Increasing patient and doctor awareness of sublingual anti-allergy tablets in the US, while at the same time cutting and rationalizing its product portfolio, are components of a new three-year business strategy aimed at making Denmark's ALK-Abello a less-niche player in the global allergy market.

EU Approvals: Evenity Cleared For Severe Osteoporosis

The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.

 

Topics

Related Companies

UsernamePublicRestriction

Register

SC124862

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel